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Spotlight On Early Career Researchers: an interview
with Lovorka Stojic
Dr. Lovorka Stojic is a postdoctoral research fellow at the University of Cambridge and will start her own research group at the
Barts Cancer Institute this fall. Her research focuses on understanding how long noncoding RNAs and RNA-binding proteins
regulate key cellular processes and how dysregulation of these processes can contribute to human diseases such as cancer. As
part of our series on early-career researchers, we asked Dr. Stojic to tell us about her research and career path. She also shares her
challenges from juggling between multiple roles and advice for job applications.
Image credit: Lovorka Stojic Please tell us about your research interests.
I am interested in how RNA-mediated mechanisms, such as those
mediated by long noncoding RNAs (lncRNAs) and RNA binding
proteins (RBP), regulate fundamental cellular processes. My
current research focuses on the regulatory principles underlying
the role of lncRNAs in cell division, and how lncRNA regulates
genome instability. To understand the function and biological
relevance of lncRNAs in the maintenance of genome stability, I
use various approaches from genomics, proteomics, imaging and
functional cell biology. Interestingly, many lncRNAs and RBPs
are dysregulated in human diseases. One of my mid-term goals is
to understand how defects in RNA regulatory networks con-
tribute to cancer. lncRNA biology really intrigues me as they have
potential to regulate gene expression at so many levels. Working
with lncRNAs often feels like solving Agatha Christie crime
mysteries, which requires great scientific skills together with an
element of pure intuition.
What has your journey been to this point?
After finishing my undergraduate degree in molecular biology at the
University of Zagreb in Croatia, I decided to do my PhD at the
University of Zurich in the laboratory of Prof. Josef Jiricny. There I
investigated how DNA repair proteins activate DNA damage
checkpoints to maintain genome stability. At the end of my PhD, I
became fascinated by epigenetics and decided to join Dr. Valerio
Orlando’s laboratory in Italy to do my first postdoc. In his
laboratory, I was introduced to key chromatin-mediated mechan-
isms that control gene expression. I then decided to move to
Cambridge (UK), where I started my second postdoc in the group
of Dr. Adele Murrell at the University of Cambridge. Her laboratory
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mainly focuses on imprinting and chromatin structure. When I
joined her lab, they had just identified a new lncRNA. LncRNAs
were being discovered rapidly at the time, many of them acting as
binding partners of Polycomb group proteins. That was the link
between my previous work and the unknown world of lncRNAs. I
will never forget the first day I joined the Murrell lab, when she told
me: “We have this cool noncoding RNA and nobody knows what it
does: it might bind Polycomb; it might regulate imprinting. Who
knows? Go and figure it out!”
I realised very quickly that if I wanted to study these lncRNAs, l had
to become familiar with key techniques. I had the fortune to receive
a CRUK Travel Award, which allowed me to visit one of the leading
labs in lncRNA biology. Being a visiting scientist in Dr. John Rinn’s
lab (then at Harvard University) was a great experience, both
professionally and personally. After my return to Cambridge from
Boston, Adele’s laboratory relocated to the University of Bath
unexpectedly. Moving again was not an option for me, also for
family reasons, so I decided to stay in Cambridge, where I took
advantage of the supervision of two senior group leaders, Dr. Fanni
Gergely and Dr. Duncan Odom. Both Fanni and Duncan gave me
the freedom to develop my own research on the role of lncRNAs for
regulation of cell division. I realised that the combination of func-
tional cell biology and genomics serves as a powerful tool to study
lncRNAs and that the expertise of the two laboratories was really
instrumental for me. My postdoctoral journey was probably unu-
sual as I had four different supervisors from completely different
fields, which all shaped me in a unique way as a scientist. It will
definitely help me establish my own research group at the Barts
Cancer Institute in London as of this September.
What are your predictions for your field in the near future?
Although lncRNAs were first discovered more than 20 years ago,
we are still learning how these RNAs operate, simply because for
many years we lacked the right experimental tools. With the
development of new biochemical methods, we are now in a better
position to decipher structural and molecular functions of
lncRNAs. However, it is challenging that some of these newly
identified lncRNAs may not be functional. Thus, we need to stay
vigilant when studying novel lncRNAs.
I see the lncRNA field moving in three directions in the foresee-
able future. First, given that a large proportion of the genome
codes for lncRNAs and that they are functionally versatile, it is not
surprising that they are often dysregulated in cancer. One of my
future goals is to understand how lncRNAs functionally contribute
to known hallmarks of cancer. Till now most of the work on the
role of lncRNAs in cancer biology has been done in cancer cell
lines, but the field is shifting towards mouse models and orga-
noids. Organoids are a good compromise between cell lines and
living animals and can be useful especially for scientists working
on human-specific lncRNAs. We can now engineer organoids and
even model human tumorigenesis in vitro. Furthermore, patient-
derived tumor organoids and/or patient-derived xenografts serve
as good models to test whether lncRNAs have a clinical potential.
Organoids are suitable for live-cell imaging, which allows one to
study dynamic processes in real time. This brings me to my sec-
ond direction, which I am personally very excited about, RNA
imaging. With the development of new tools used to image RNA
at the single-molecule level, we can now track lncRNAs in living
cells, and ask so many questions about their role in cell cycle
progression. Third direction is epitranscriptomics. We know very
little about dynamics and functions of different RNA modifica-
tions on lncRNAs and how these RNA modifications affect their
structure, stability, localisation as well as cellular processes they
regulate. With the development of new high-throughput mapping
approaches and functional studies, we will learn more about the
importance of RNA modifications and their contribution to dif-
ferent cellular processes and diseases.
Can you speak of any challenges that you have overcome?
It was challenging for me to go back to the lab after both of my
maternity breaks during my postdoctoral training in Cambridge, and
to coordinate my work with parenting. I often found myself reading
papers while waiting for my kids’ football games or swimming to end.
My personal challenge is trying to be a good mother, partner, sci-
entist, and mentor at the same time. Another scientific challenge,
which nobody prepares me for, is the transition from a postdoc to a
group leader position. As someone who will soon start an indepen-
dent research group, I can only say that you need to be persistent,
resilient, and have a thick skin. Every unsuccessful interview presents
an opportunity to learn more for a better interview, until you are
ready for the right job. It takes time to master your job application
skills, which means that you have to take the best out of rejections
and ask for feedback after each interview.
What advice would you give to your younger self?
Follow what your science leads you to and stay enthusiastic about
your research. At the same time, take criticism from your peers,
colleagues, and collaborators. Don’t be afraid to reach out for help
if needed, and start to network as early as you can. You never
know when you will need it.
What is your favourite RNA?
Any long noncoding RNA that is functional.
This interview was conducted by Associate Editor Jung-Eun Lee.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© Springer Nature Limited 2019
Q&A COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0466-7
2 COMMUNICATIONS BIOLOGY |           (2019) 2:204 | https://doi.org/10.1038/s42003-019-0466-7 | www.nature.com/commsbio
